{"id":305109,"date":"2024-07-29T00:00:00","date_gmt":"2024-07-29T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0250-biopharma-marginal-zone-lymphoma-epidemiology-epidemiology-marginal-zone-lymphoma\/"},"modified":"2026-03-31T10:29:08","modified_gmt":"2026-03-31T10:29:08","slug":"epidon0250-biopharma-marginal-zone-lymphoma-epidemiology-epidemiology-marginal-zone-lymphoma-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0250-biopharma-marginal-zone-lymphoma-epidemiology-epidemiology-marginal-zone-lymphoma-mature-markets\/","title":{"rendered":"Marginal Zone Lymphoma &#8211; Epidemiology &#8211; Epidemiology &#8211; Marginal Zone Lymphoma &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of marginal zone lymphoma (<abbr title=\"marginal zone lymphoma\">MZL<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence of <abbr title=\"marginal zone lymphoma\">MZL<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"marginal zone lymphoma\">MZL<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"marginal zone lymphoma\">MZL<\/abbr> over the forecast period?<\/li>\n<li>Of all people diagnosed with <abbr title=\"marginal zone lymphoma\">MZL<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.<\/p>\n<p>In addition to the total number of incident cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"marginal zone lymphoma\">MZL<\/abbr> subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of extranodal <abbr title=\"mucosa-associated lymphoid tissue\">MALT<\/abbr> <abbr title=\"marginal zone lymphoma\">MZL<\/abbr> with baculoviral <abbr title=\"inhibitor of apoptosis protein\">IAP<\/abbr> repeat-containing 3-mucosa-associated lymphoid tissue lymphoma translocation gene 1 (BIRC3-MALT1) fusion.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"marginal zone lymphoma\">MZL<\/abbr>.<\/li>\n<li>Diagnosed drug-treatable cases.<\/li>\n<li>Diagnosed drug-treated cases.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-305109","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305109\/revisions"}],"predecessor-version":[{"id":305665,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305109\/revisions\/305665"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=305109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}